A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors.
Antonio Jimeno
Research Funding - OncoMed
Michael S. Gordon
No relevant relationships to disclose
Rashmi Chugh
No relevant relationships to disclose
Wells A. Messersmith
Consultant or Advisory Role - OncoMed (U)
Research Funding - OncoMed
David S. Mendelson
No relevant relationships to disclose
Jakob Dupont
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Robert J. Stagg
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Ann Kapoun
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Lu Xu
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Rainer Karl Brachmann
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
David C. Smith
Research Funding - OncoMed